Four Korean women's health companies. Clinical innovation — diagnostics, devices, digital health. Not wellness. What they need is the room: New Jersey's women's health institutions.
The program runs on pre-designed curated meetings and private introductions — not a trade-show floor.
Co-hosted with Choose New Jersey, the state's official economic-development agency, and the Hudson County Chamber — Korean Chapter.
In 2025 the Korean delegation visited NJEDA, BioNJ, RWJBarnabas Health, Hackensack Meridian, and Rutgers — with support from the office of U.S. Senator Andy Kim.
A small, focused cohort so every participating company gets real attention — as a peer, not a vendor.
New Jersey is the largest life-sciences region in the U.S. Northeast — twenty minutes from Manhattan, dense with leading women's health systems and the clinical networks that validate new technology. For Korean companies, it is the shortest, most credible route into the American market.
Hospital networks with strong women's health, OB-GYN, and breast programs — for clinical validation and pilot conversations.
IVF and fertility institutes — the direct counterpart for Korea's fertility technology companies.
Cancer and diagnostic programs — where AI screening devices prove their value.
University medical faculty — research collaboration and clinical credibility.
We are looking for diagnostics, devices, therapeutics, and digital health. Wellness products are not the target.
Selects the four companies. Sets direction and secures keynotes. Owns interpretation, pre-curated 1:1 meetings, cohort lunches, press and filming, and post-event follow-up.
Builds the program and schedule. Opens the New Jersey doors — connecting the women's health institutions and clinical partners best matched to this cohort.
Four seats. Korea's most clinically serious women's health innovators, in front of the New Jersey institutions that decide adoption.